文献速递炎症性肠病

JAK抑制剂治疗急性重度溃疡性结肠炎:乌帕替尼与托法替布及挽救与序贯挽救治疗比较

Janus Kinase Inhibitors for Acute Severe Ulcerative Colitis: Comparing Upadacitinib to Tofacitinib and Rescue to Sequential Salvage therapy.
PubMed 文献 · Clin Gastroenterol Hepatol · 2026-10-06

这项多中心回顾性队列研究纳入150例急性重度溃疡性结肠炎(ASUC)患者,比较乌帕替尼与托法替布、以及挽救治疗与序贯挽救治疗的效果。第52周结肠切除率为33%,乌帕替尼组显著低于托法替布组(23.4% vs 42.5%,p=0.022)。序贯挽救治疗结肠切除率数值上高于挽救治疗(38% vs 30%),但差异无统计学意义。

要点

  • 乌帕替尼治疗ASUC第52周结肠切除率显著低于托法替布(23.4% vs 42.5%)。
  • 序贯挽救治疗结肠切除率38% vs 挽救治疗30%,差异无统计学意义。
  • JAK抑制剂用于ASUC总体有效且安全性良好。

核心结论

  • JAK抑制剂治疗ASUC有效且安全性良好,乌帕替尼第52周结肠切除率显著低于托法替布。
  • 序贯挽救治疗可作为面临结肠切除患者的可行选择,但结肠切除率与挽救治疗差异未达统计学意义。

研究设计与样本

  • 多中心回顾性队列研究,覆盖澳大利亚13个IBD中心。
  • 纳入2021年4月至2024年4月启动乌帕替尼或托法替布治疗的成人ASUC患者,共150例,随访至52周。

主要发现

  • 乌帕替尼使用占51%,托法替布占49%;JAK抑制剂作为挽救治疗占69%,作为序贯挽救治疗占31%。
  • 第52周结肠切除率总体为33%,乌帕替尼组23.4%显著低于托法替布组42.5%(加权边际风险差-0.18,p=0.022),但早期时间点无显著差异。
  • 序贯挽救治疗结肠切除率38% vs 挽救治疗30%(校正边际风险差-0.1,p=0.239),差异无统计学意义。
  • 乌帕替尼组随访期间临床缓解、无激素临床缓解(CFCR)和生化缓解率更高。

临床怎么用

  • ASUC患者可考虑使用JAK抑制剂作为挽救治疗,乌帕替尼在降低52周结肠切除率方面可能优于托法替布。
  • 对面临结肠切除的患者,序贯挽救治疗可作为可选策略,但需权衡获益与风险。

局限性

  • 回顾性队列设计可能存在选择偏倚和混杂因素。
  • 样本量150例,序贯挽救治疗比较未达统计学显著性,需更大样本验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acute Severe Ulcerative Colitis (ASUC) remains a medical emergency with limited therapeutic options. Upadacitinib and tofacitinib are Janus kinase (JAK) inhibitors being increasingly used as rescue therapy for ASUC with limited data. We evaluated outcomes of JAK inhibitor use for ASUC over 52 weeks. METHODS: We undertook a multicentre retrospective cohort study across 13 Australian IBD centres. Adults with ASUC who commenced upadacitinib or tofacitinib from April 2021 to April 2024 were included. Outcomes were assessed during index admission, at week 8, 16, and 52. Comparisons of upadacitinib vs tofacitinib and rescue vs sequential salvage therapy were undertaken. The primary outcome for both analyses was colectomy by week 52. RESULTS: 150 patients were included with complete follow-up to 52 weeks. Upadacitinib was used in 51%, tofacitinib in 49%; JAK inhibitors as rescue therapy in 69% and sequential salvage therapy in 31%. Colectomy occurred in 33% of patients by week 52, and was significantly lower with upadacitinib than tofacitinib (23.4% vs 42.5%, weighted marginal risk difference -0.18, p=0.022), with no significance at earlier timepoints. Sequential salvage therapy resulted in a numerically higher rate of colectomy compared to Rescue therapy (38% vs 30%, adjusted marginal risk difference -0.1, p=0.239), but did not meet statistical significance. CONCLUSION: JAK inhibitors were effective for ASUC with a reassuring safety profile. Upadacitinib use resulted in a significantly lower rate of colectomy by week 52, with higher rates of clinical remission, CFCR, and biochemical remission during follow-up. Sequential salvage therapy may represent a viable therapeutic option for patients otherwise facing colectomy.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Gilmore R, Fernandes R, Goetz N, et al. Janus Kinase Inhibitors for Acute Severe Ulcerative Colitis: Comparing Upadacitinib to Tofacitinib and Rescue to Sequential Salvage therapy. Clin Gastroenterol Hepatol. 2026. PMID: 42838313. doi:10.1016/j.cgh.2026.10.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。